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The aim of the present study was to evaluate the change of thymidine phosphorylase (TP) activity in gastric adenocarcinoma and 
adjacent tissue upon the intraarterial administration of 5-fluorouracil (5-FU). Matherials and methods: The specimens of tumor 
and adjacent tissue were obtained by surgical operation on 36 patients (20 men and 16 women aged from 38 to 82 years) with 
gastric adenocarcinoma (stages II–IV). 5-FU was administered in the bolus dose to the gastroepiploic artery 2–60 min before 
the tumor resection. The concentration of 5-FU and activity of TP in both tissues were determined by high performance liquid 
chromatography method. Results: The concentration of 5-FU was decreased in a time-dependent manner in both tissues, though 
the interpatient variability of this value was much less in tumor tissue. The activity of TP was decreased with the course of the time 
after 5-FU administration in tumor and normal adjacent tissue. There were statistically significant differences in the TP activity 
in both tissues between 2–20 min and 40–60 min after 5-FU injection (p < 0.05). Conclusion: 5-FU administration results in the de-
crease of TP activity in tumor and normal adjacent tissues that might have importance for chemotherapy with fluoropyrimidines.
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Chemotherapy with fluoropyrimidines — 5-fluoro-
uracil (5-FU) and its derivatives (capecitabine, tega-
fur, etc.) is nowadays the standard for the treatment 
of gastric adenocarcinoma (GAC) [1]. Thymidine 
phosphorylase (TP) is a key enzyme of these drugs ac-
tivation which catalyzes transformation of capecitabine 
to 5-FU and further — 5-FU — to 2-deoxy-5-fluorouri-
dine. This enzyme plays an important role in the patho-
genesis of tumor growth and in many respects deter-
mines the efficacy of the chemotherapy of oncological 
diseases, meanwhile the role of TP is dual.
On the one hand, TP is considered as a negative 
prognostic factor for GAC and other cancer types be-
cause of its participation in the processes of angioge-
nesis and apoptosis. Various studies testify it's identity 
with the platelet-derived endothelial growth factor [2, 
3]. It was shown that TP induces endothelial cells mi-
gration that intensifies vascular invasion in tumor [4, 5]. 
Inhibitory effect of TP on cancer cells apoptosis was 
demonstrated on the different cell lines [6]. In the solid 
tumors the hyperproduction of TP comparing to normal 
tissues is observed [3, 7].
On the other hand, at the chemotherapy with 
fluoropyrimidines the hyperexpression of TP in tu-
mors of different localizations guaranties the increase 
of the production of active metabolites of these drugs 
in tumor as compared to normal tissue. Thus, due 
to the catalytic activity of TP capecitabine promotes 
the maximal cytostatic effect on the tumor under 
the minimal influence on normal tissues [8]. Therefore 
the determinant factor of fluoropyrimidines pharma-
codynamics is the activity of TP both in tumor and 
normal tissues.
The aim of the present study was to investigate 
TP activity in GAC and adjacent tissue upon the intra-
arterial administration of 5-FU.
MATERIALS AND METHODS
Patients. The specimens of tumor and normal adja-
cent tissue (gastric mucosa without signs of mali gnant 
transformation or inflammation) obtained in surgical 
operation from 36 patients (20 men and 16 women 
aged from 38 to 82) with GAC on different stages (II–IV) 
were used. Study was approved by the Ethic Committee 
of M. Gorky Donetsk National Medical University.
Patients were treated with the intraarterial chemothe-
rapy in the neoadjuvant regimen. 5-FU was administered 
in the bolus dose to the gastroepiploic artery 2–60 min 
before the tumor resection. Tissue specimens were frozen 
and stored under −70 °С till use. The mucosa samples were 
taken at a distance of 5–7 cm from the tumor node edge.
Tissues were homogenized on ice  wi th 
35 mM KH2PO4/Na2HPO4 buffer, pH = 7.4 (ratio 
of specimen weigh to buffer was 1:20). All reagents 
used in the present study were intended for high per-
formance liquid chromatography (HPLC).
Determination of 5-FU concentration. The con-
centration of 5-FU in tissues was determined by the me-
thod of N. Christophidis [9] which involved the double 
extraction of 5-FU from the homogenate and further mea-
surement of concentration by means of HPLC. Ethylace-
tate was added to the tissue homogenate, vortex mixed 
over 90 s and centrifuged during 3 min at 855 g. The upper 
organic layer was collected to the tube with alkaline buf-
fer (Na2HPO4 mixed with NaOH till pH = 11.0). The tube 
content was vortex mixed again and centrifuged as de-
scribed above. The supernatant was collected and used 
for 5-FU concentration measurement.
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5-FU concentration was determined with HPLC-
system (Konikrom Plus, Konik Group, Spain) with PDA-
detector and chromatographic column (250x4.6 mm, 
YMC Europe GmbH, Germany). For elution 20 mM am-
monium chloride solution with 2% of acetonitrile was 
used. For the calculation of 5-FU concentration 
the calibration curve (correlation coefficient R = 0.99) 
after the above described preparation was used.
Determination of TP activity. TP activity in the tis-
sues homogenates was determined by the accumula-
tion of thymine — the product of thymidine phospho-
rolysis, by the method of van Kuilenburg [10].
The reaction mixture consisted of 35 mM KH2PO4/
Na2HPO4 (pH = 7.4), 1 mM of mercaptoethanol and 
2 mM of thymidine. Reaction was started by the addition 
of homogenate to the reaction mixture. At once after 
(1 probe) and in 45 min of incubation at 37 °С (2 tube) 
reaction was stopped by addition of acetonitrile. Proteins 
were removed after centrifugation at 12 000 g during 
15 min, after that acetonitrile was removed by chloroform. 
The concentration of thymine was determined by means 
of HPLC as described above for 5-FU. The total protein 
concentration in homogenate was measured by Lowry 
method [11]. TP activity was calculated as the difference 
between the level of thymine on 45 min (2 probe) and 
0 min (1 probe) with account of protein concentration 
in probe and presented in μmol/mg per min.
The statistical data processing was made with 
the help of Statistica 6.0 software (Statsoft Inc.).
RESULTS
5-FU concentration in tissues. In tumor tissue 
there was the negative correlation between the con-
centration of 5-FU and the time after its administration 
(r = −0.83, р < 0.05) (Fig. 1).
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Fig. 1. Concentration of 5-FU in gastric tumor (a) and adjacent 
mucosa (b) in different periods after 5-FU administration
The maximal value of 5-FU  concentration 
was 41.35 μmol/g on the 2 min, minimal — 
0.24 μmol/g in 1 h after injection. The two fold decrease 
of 5-FU in tumor was detected already in 10 min. 
In the first 30 min after injection 5-FU level was decreased 
by 80%, the rest 20% was degraded during next 30 min.
In adjacent mucosa the correlation between drug 
concentration and time was lower than in tumor 
(r = −0.39, р < 0.05). The peak 5-FU concentration 
was 108.3 μmol/g (in the tissue resected in 15 min after 
5-FU injection), the lowest value of 5-FU concentra-
tion was 0.01 μmol/g (in 60 min after 5-FU injection).
TP activity in tissues. In the initial period TP acti-
vity in tumor was much higher than in adjacent mucosa. 
With the course of time after 5-FU injection in both tis-
sues the decrease of TP activity was observed (Fig. 2).
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Fig. 2. TP activity in tumor (a) and adjacent mucosa (b) in dif-
ferent periods after 5-FU administration
There was a moderate correlation between 
TP activity and time after injection both in tumor 
(R = −0.63; р < 0.05) and adjacent mucosa (R= −0.64; 
р < 0.05). The mean value of TP activity (26.8 and 
6.4 μmol/mg per min in tumor and adjacent tissue re-
spectively) was significantly lower in the samples on 40–
60 min after 5-FU injection as compared to the samples 
resected on 2–20 min (86.9 and 25.3 μmol/mg per min 
in tumor and adjacent tissue, respectively). In both 
cases the difference according to Mann — Whitney test 
was significant (p = 0.012 in tumor and p = 0.008 in ad-
jacent tissue).
DISCUSSION
The obtained data testify that the intraarterial injec-
tion of 5-FU to gastroepiploic artery leads to the grad-
ual decrease of 5-FU concentration in the gastric 
tumor tissue. The type of this dependence is similar 
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to the pharmacokinetic curves for 5-FU in the blood 
plasma; however in contrast to standard pharmacoki-
netic studies in the present study the data from diffe-
rent patients was used. Besides that the pharmacoki-
netic parameters are also similar: in the present study 
5-FU concentration in tumor was decreased 2-fold 
in the first 10 min that approximately corresponds 
to 5-FU half-life time in blood [12].
In the adjacent tissue the interindividual difference 
of 5-FU degradation rate was more expressed but with-
in one hour drug concentration was also significantly 
decreased. The fundamental differences between 
the metabolic processes in tumor and normal tissues 
might be a reason for the observed disappearance 
of the interindividual variability in tumor comparing 
to adjacent tissue.
It is notably that together with decreasing of drug 
concentration with the time after its injection TP ac-
tivity lowered in both investigated tissues. According 
to the obtained data during the study period enzyme 
activity in tumor lowers 1.5-fold, in the adjacent tis-
sue — 2.8-fold. There may be the following reasons 
below for such influence of 5-FU load on TP activity.
5-FU is an effective cytostatic agent which action 
leads ultimately to the suppression of protein synthesis 
in the cell. So one possible way of its action on TP may 
be the inhibition of this enzyme gene expression ei-
ther on the stage of mRNA synthesis or on the stage 
of translation. These effects are characteristic for 
other antimetabolites. It was shown that cancer chemo-
therapy alters gene expression in tumor and adjacent 
tissue of patients with rectal cancer [7]. Some chemo-
therapeutic drugs (cisplatin, camptothecin, paclitaxel) 
when incubated with human colon cancer cell lines 
decrease TP expression [13]. In this context the fact 
that 5-FU influence on TP activity develops already 
in the first hour after drug administration to the patients 
assumes that the rate of this enzyme synthesis is high 
as compared to the synthesis of other cell proteins, i.e. 
it is possible that the half-life time of TP is not longer 
than one hour. Currently there is no data concerning 
TP protein turnover rate. But according to the data 
of research [14] dedicated to the study of more than 
5 000 cell proteins the half-life time of proteins varies 
a lot at that the minimal half-life is about 45 min. Thus, 
decrease of TP amount in the cell under the action 
of 5-FU is theoretically possible in the case this enzyme 
has the short half-life time, i.e. high turnover rate.
Another possible mechanism of drug influence is that 
by means of direct interaction with TP the metabolites 
of 5-FU may inhibit its activity. The option that 5-FU it-
self interacts with TP protein is not in question because 
5-FU is the substrate of TP. In this case enzyme activity 
might be low at once after drug injection when the con-
centration of the drug was on the peak level. The gradual 
non-sharp decrease of TP activity after 5-FU load testifies 
the decrease of its amount but not the activity.
The fact that 5-FU administration results in the de-
crease of TP level may be of importance for the ef-
ficacy of the chemotherapy. In the meantime this fact 
has the double meaning because TP plays a dual role 
in the pathogenesis of oncological diseases.
As mentioned above, TP participates in the activation 
of 5-FU and other fluoropyrimidines. In this regard sup-
pression of TP may result in the decrease of the concen-
tration of active metabolites of 5-FU in tissues. This will 
weaken the required “useful” effect of cytostatic on tumor.
In the meantime there are several reasons for con-
sidering TP inhibition as the aim of various anticancer 
chemotherapies. TP expression positively correlates 
with microvessel density, tumor grade, disease stage 
and metastasis. High TP level in tumor is associated with 
poor prognosis and reduction of overall survival [3, 15]. 
For the cell lines expressing TP the increase of migra-
tion and invasive activity is characteristic [16]. Besides 
that TP suppresses the hypoxia-induced apoptosis 
of cancer cells [4, 6]. Inhibition of TP by various agents 
(e.g., 5-bromo-6-aminouracil) induces tumor cells 
apoptosis [2]; and the antiproliferative action of met-
formin is supposed to be associated with the decrease 
of TP expression under the action of this drug [17].
In the present study patients received one dose 
of 5-FU that was followed by lowering of TP activity for 
at least 1 h after injection. Therefore, it’s arguable that 
long-term infusions of 5-FU used in clinical practice 
may result in consistent suppression of TP activity. 
In this case the process of 5-FU activation will definitely 
slow down. At the same time the long-term inhibition 
of TP may stipulate decrease of metastasis and promote 
apoptosis of cancer cells. So for the result of the therapy 
the important role plays the balance between two effects: 
negative — decrease of fluoropyrimidines transformation 
to the active metabolites, and positive — suppression 
of TP as the negative factor of disease development.
Thus, in the present study it was found that intraarte-
rial injection of 5-FU provides decrease of TP activity for 
up to 1 h after drug administration in both gastric tumor 
and normal adjacent mucosa.
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